? ? The efficacy of Buprenorphine (Bup) as a treatment for opioid dependence has been established in trials that included on-site drug counseling. In an effort to expand access to treatment for opioid dependence, new regulations make Bup available in primary care without obligate counseling. Despite evidence demonstrating improved outcomes when drug counseling is provided along with methadone treatment in opioid treatment programs, no such evidence exists for Bup treatment in primary care. Emerging evidence indicates that PCC physicians offering Bup treatment will likely provide a low level of counseling services, consistent with the minimum requirements under federal regulations, due to fiscal, logistical and competency constraints. Our studies of Bup in primary care demonstrate the feasibility of on-site drug counseling; great variability in Bup adherence and a strong association between improved Bup adherence and improved outcomes; the importance and fragility of early abstinence; and frequent relapse within 6 months even among patients who achieve sustained abstinence during initial 6 months of treatment. To evaluate the need for drug counseling aimed at reducing illicit drug use and increasing Bup adherence, the proposed study compares manual-guided Physician Management (PM) and PM combined with on-site manual-guided Cognitive Behavioral Therapy (CBT) in a 24 week randomized clinical trial of Bup in a heterogeneous population of opioid dependent patients (N=140) in a primary care clinic. PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services. CBT will be provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Bup adherence. The study will test the hypothesis that that the addition of CBT to PM will lead to decreased illicit drug use, durable effects after counseling has been discontinued, improved Bup adherence and will demonstrate incremental cost-effectiveness in patients receiving Bup maintenance in primary care. Primary outcome measures include reductions in illicit opioid use and abstinence achievement, as assessed by weekly urine toxicology testing and self report. Secondary outcome measures include retention in treatment, reductions in cocaine use and HIV risk, decreased criminal activity and improved health and employment status. Utilization and costs of services, spillover effects in the PCC, and patient and staff perceptions of benefits and problems associated with primary care agonist maintenance treatment will also be evaluated. The results of this study will help define the role of professional evidence-based drug counseling in expanding access to treatment with Bup. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA019511-01
Application #
6904346
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Denisco, Richard A
Project Start
2005-08-20
Project End
2010-07-31
Budget Start
2005-08-20
Budget End
2006-07-31
Support Year
1
Fiscal Year
2005
Total Cost
$615,550
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Moore, Brent A; Fiellin, David A; Cutter, Christopher J et al. (2016) Cognitive Behavioral Therapy Improves Treatment Outcomes for Prescription Opioid Users in Primary Care Buprenorphine Treatment. J Subst Abuse Treat 71:54-57
Oberleitner, Lindsay M; Beitel, Mark; Schottenfeld, Richard S et al. (2016) Drug Counselors' Attitudes Toward Nonpharmacologic Treatments for Chronic Pain. J Addict Med 10:34-9
Fiellin, David A; Barry, Declan T; Sullivan, Lynn E et al. (2013) A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 126:74.e11-7
Barry, Declan T; Savant, Jonathan D; Beitel, Mark et al. (2013) Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am J Addict 22:212-7
Moore, Brent A; Fazzino, Tera; Barry, Declan T et al. (2013) The Recovery Line: A pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance. J Subst Abuse Treat 45:63-9
Dreifuss, Jessica A; Griffin, Margaret L; Frost, Katherine et al. (2013) Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend 131:112-8
Savant, Jonathan D; Barry, Declan T; Cutter, Christopher J et al. (2013) Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend 127:243-7
Moore, Brent A; Barry, Declan T; Sullivan, Lynn E et al. (2012) Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med 6:205-11
Barry, Declan T; Savant, Jonathan D; Beitel, Mark et al. (2012) Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone. J Addict Med 6:274-9
Tetrault, Jeanette M; Tate, Janet P; McGinnis, Kathleen A et al. (2012) Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res 36:318-24

Showing the most recent 10 out of 24 publications